Work

Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial

Year: 2020

Type: article

Source: Lung Cancer

DOI: 10.1016/s0169-5002(20)30164-1

Authors: R. Califano, D. Camidge, H.-R. Kim, M.-J. Ahn, J. Yang, J.-Y. Han, M. Hochmair, K.H. Lee, A. Delmonte, M.R. Garcia Campelo, D.-W. Kim, F. Griesinger, E. Felip, A. Spira, S. Gettinger, M. Tiseo, Q. Ni, P. Zhang, S. Popat

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3003397180

FWCI: 0.282

Cites:

Cited by: 2

Related to: 10